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SummArY – Prostate cancer (PC) is known as an androgen-dependent tumor with testosterone 
as its natural growth factor, its action is mediated by the androgen receptor (Ar) important for the 
biology and progression of PC. during aging a progressive decline in testosterone levels begins, caused 
by disability of aged leydig cells to produce testosterone in response to luteinizing hormone. Surgical 
treatment of PC can influence the hypothalamic-pituitary-gonadal axis with less impact on it com-
pared to patients treated with radiation. Patients with pre-operative low baseline testosterone level had 
mean gleason score higher and Ar expression was higher; significantly lower testosterone levels were 
recorded in patients with lymph node metastases. But some data are conflicting, and some results are 
opposite to those mentioned before. These data show that there is no significant association between 
all sex hormone in men and lethal PC or total mortality. In patients with metastatic PC, results 
showed that elevation of baseline androstenedione levels was predictive of prostate-specific antigen 
(PSA) response; higher baseline androstenedione levels were associated with an improved overall 
survival. In these patients, the relationship between serum testosterone and PC prognosis varies in 
different clinical settings and according to androgen deprivation therapy administration.
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Prostate cancer (PC) is one of the most frequent 
cancers in male population (second place by incidence, 
behind lung cancer) and also one of the leading causes 
of cancer-related deaths.1 during the last few decades, 
use of prostate specific antigen (PSA) testing has led 
to an increase in incidence but also significant propor-
tion of patients was diagnosed in a much earlier stage 
of disease which allows wider treatment options and 
better prognosis. however, for patients diagnosed with 
recurrent or disseminated disease, treatment options 
are more limited, and prognosis is worse.2,3
Prostate cancer is known as an androgen-dependent 
tumor with testosterone as its natural growth factor. Its 
action is mediated by the androgen receptor (Ar) which 
is hormone-activated transcription factor important for 
the biology and progression of PC.4 testosterone can 
stimulate PC progression, it has been observed in PC 
patients with „flare phenomenon“ when luteinizing 
hormone-releasing hormone (lhrh) analog adminis-
tration causes transient increase in serum testosterone 
levels.5 Androgen deprivation therapy (Adt) plays the 
central role in PC treatment and leads to beneficial re-
sponses in most patients with advanced disease.6 unfor-
tunately, some patients develop the castration-resistant 
disease as a result of Ar amplification as the most im-
portant molecular alteration.4
treatment options for localized PC are surgery 
(radical prostatectomy) or radiation, with or without 
Adt, and treatment options for locally advanced and 
disseminated PC are radiation with Adt, Adt alone 
or in combination with chemotherapy.4
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The aim of this review is to compare prognostic 
value of testosterone in treatment of localized PC, ad-
vanced PC either before or during Adt, and in castra-
tion-resistant PC.
Testosterone decline with age
Androgens are essential for male sexual maturity. 
testosterone regulates muscle development and 
 gonadotropin secretion; dihydrotestosterone (dht) 
regulates spermatogenesis and all other factors of male 
sexual maturity (hair growth, acne, male pattern bald-
ness, etc.).7 Pituitary luteinizing hormone (lh) stim-
ulates leydig cells in the testicular interstitium to pro-
duce testosterone. Progressive decline in circulating 
testosterone levels begins after puberty.8
testosterone decline is associated with type II dia-
betes mellitus, dyslipidaemia, arterial hypertension, 
osteoporosis, muscle weakness, sexual dysfunction, de-
pressed mood, etc. In general, testosterone decline in-
creases the risk of all-cause and cardiovascular mortal-
ity.9 The main cause of testosterone decline is the dis-
ability of aged leydig cells to produce testosterone in 
response to lh; there is no decline in number of ley-
dig cells or circulating lh levels with age. testoster-
one decline is a result of complex functional changes in 
expression of steroidogenic enzymes, supply of choles-
terol precursors to steroidogenic pathway, expression 
and function of mitochondrial cholesterol transport 
machinery (StAr protein and tSPo), expression of 
CoX-2 gene which is inhibitor of StAr protein ex-
pression and leydig cell steroidogenesis. Also, there 
are changes in cAmP signal which decline ability of 
leydig cells to produce steroids and availability of tes-
tosterone precursor to steroidogenesis.8
Testosterone levels after prostate surgery
Surgical treatment of PC can influence the hypo-
thalamic-pituitary-gonadal axis confirming the role of 
the prostate as an active endocrine organ. radical 
prostatectomy (rP) increases testosterone and per-
cent-free testosterone, estradiol, lh and follicle stim-
ulating hormone (FSh) serum levels and decreases 
dht serum level in one-year period.10
In comparison with external beam radiation thera-
py (eBrt) there is less impact on hypothalamic-pitu-
itary-gonadal axis in patients treated surgically.11
In patients with lower urinary tract symptoms 
(lutS) treated with conservative therapy or transure-
thral resection of the prostate (turP) there were no 
significant endocrine changes in 12 months period. 
Same study shows that baseline testosterone level is 
almost twice higher in the low-grade tumors group 
(gleason score ≤6) than in the high-grade tumors 
group (gleason score 7-10). Conversely, the results 
showed doubling of testosterone in 12-months-period 
in the high-grade tumors group in comparison to the 
low-grade tumors group.12
The influence of the testosterone in localized PC
Serum testosterone levels are associated with the 
prostate-specific antigen (PSA) levels, gleason score 
and Ar expression in newly diagnosed PC patients. In 
one retrospective study, men with low baseline testos-
terone level (<3,0 ng/ml) had lower levels of lh, FSh 
and estradiol, PSA levels were lower, but mean glea-
son score was higher. In these patients Ar expression 
was higher in comparison to normal and high testos-
terone group.13
Another retrospective study of patients treated by 
rP showed connection between low baseline testos-
terone levels and increased body mass index and dia-
betes mellitus. more important, significantly lower 
testosterone levels were recorded in patients with 
lymph node metastases compared to patients with 
non-metastatic disease.14
In one large retrospective study, low baseline tes-
tosterone levels at diagnosis of PC were associated 
with aggressive type of PC and predicted poor PC-
specific survival. testosterone baseline levels signifi-
cantly decreased as PC aggressiveness increased; the 
low testosterone group had 2,9-fold increased risk for 
intermediate-risk PC, 5,6-fold increased risk for high-
risk PC, and 72,4-fold increased risk for metastatic 
PC compared with the normal testosterone group. 
Furthermore, the low testosterone group had 10,7-fold 
increased risk of the PC-specific mortality.15
There are data about patients with unfavorable-risk 
PC treated in prospective clinical trials with radiothera-
py and Adt and their testosterone levels at the time of 
first PSA failure. low (but not necessarily castration) 
testosterone levels at the time of first PSA failure confer 
a very poor prognosis, a significant increase in the risk of 
all-cause mortality and PC-specific mortality.16
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recent study from 2019 investigated the role of 
baseline free and total testosterone levels on post-op-
erative oncologic outcomes, continence and erectile 
function. low baseline free testosterone level was re-
lated to higher risk for pt3 PC and higher gleason 
score; furthermore, it was an independent risk factor 
for biochemical recurrence in 52 months period. Base-
line total testosterone level was related to pre-opera-
tive erectile dysfunction (ed) and baseline free testos-
terone level was related to post-operative ed in logis-
tic regression.17
But some data are conflicting, and some results are 
opposite to those mentioned above. result from the 
two large prospective cohort studies showed no sig-
nificant association between quartile of total testoster-
one, sex hormone binding globulin (ShBg), ShBg-
adjusted testosterone, free testosterone, dht, andro-
stanediol glucuronide or estradiol and lethal PC or 
total mortality. Also, there was no consistent associa-
tion between lethal PC and sex hormone quartile in 
subset analyses stratified by gleason score, tnm stage 
and age.18
Another study included two Phase III trials involv-
ing Adt and eBrt to assess the significance of a 
baseline testosterone levels. results showed indepen-
dent influence of age, gleason score and PSA on an 
increased risk of biochemical relapse, metastatic disease 
and reduced cause-specific and overall survival. Baseline 
testosterone level doesn’t affect these outcomes in pa-
tients treated with eBrt and Adt for PC.19
one collaborative analysis of 20 prospective studies 
showed that men with lowest free testosterone level 
had a lower risk of overall PC than men with higher 
concentration of free testosterone. Significant hetero-
geneity was present by tumor grade; very low free tes-
tosterone levels were associated with a lower risk of 
low- and intermediate-grade disease and a no signifi-
cantly higher risk of high-grade disease.20
The influence of testosterone in metastatic PC
As it is already mentioned, Adt plays a central 
role in PC treatment leading to beneficial responses in 
most patients with advanced disease, but some patients 
develop the castration-resistant disease as a result of 
Ar amplification as the most important molecular al-
teration.4 one multicenter randomized phase III clini-
cal trial (CAlgB 9583) evaluated adrenal androgen 
levels as predictors of outcome in PC patients treated 
with ketoconazole plus antiandrogen withdrawal. PSA 
response rate was almost 30% and median response 
duration was approximately 5 months. univariate 
analysis showed that elevation of baseline androstene-
dione levels was predictive of PSA response. In multi-
variate analysis, in comparison to lower tertile baseline 
androstenedione levels, both the uppermost and the 
middle tertile of baseline androstenedione level were 
associated with an improved overall survival.21
Phase III study (Cou-AA-301) showed that abi-
raterone acetate (AA) in combination with prednisone 
prolonged overall survival in patients with metastatic 
castration-resistant prostate cancer (mCrPC) after 
administration of docetaxel. In bivariate and multi-
variable analyses baseline androgen levels were strong-
ly associated with survival. Baseline androgen levels 
above median compared with below median in both 
the AA+prednisone and prednisone group resulted 
with longer survival. treatment with AA+prednisone 
resulted with longer survival versus prednisone alone 
in the above- or below-median group for all andro-
gens.22
In the next study, a prognostic and predictive value 
for survival and response to salvage hormonal therapy 
of baseline testosterone level was analyzed in mCrPC 
patients from nine different non-hormonal first-line 
chemotherapy phase II–III trials. median overall sur-
vival was significantly longer if baseline testosterone 
level was above, rather than under the testosterone 
level median value. The presence of anemia in these 
patients was an unfavorable prognostic factor; the 
presence of low testosterone level and anemia had a 
worse outcome compared to those with one or none of 
them.23
large systematic review and meta-analysis in 2018 
investigated 25 studies for the independent relation-
ship between serum testosterone and prognosis of PC 
patients. The prognostic value of testosterone was eval-
uated in early-stage PC in 8 studies, in advanced PC 
before Adt in 4 studies, in advanced PC during Adt 
in 5 studies and in mCrPC in 8 studies. Serum testos-
terone level was not prognostic in terms of overall sur-
vival and biochemical recurrence in early-stage PC 
studies. In advanced PC studies, higher testosterone 
levels before Adt were associated with a reduced risk 
of death; but during Adt, lower testosterone levels 
were associated with a reduced risk of death and PC 
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progression. In mCrPC studies, higher testosterone 
levels predicted a reduced risk of PC progression, but 
not of death. The heterogeneity of the included studies 
was a major limitation of this meta-analysis. In con-
clusion, the relationship between serum testosterone 
and PC prognosis varies in different clinical settings 
and according to Adt administration.24
Conclusions
Prostate cancer is known as an androgen-depen-
dent tumor with testosterone as its natural growth fac-
tor, its action is mediated by the androgen receptor 
(Ar) important for the biology and progression of PC. 
Adt plays the central role in PC treatment leading to 
beneficial responses in most patients with advanced 
disease. Some patients develop the castration-resistant 
disease as a result of Ar amplification as the most im-
portant molecular alteration.4 Surgical treatment of 
PC can influence the hypothalamic-pituitary-gonadal 
axis with less impact on it compared to patients treated 
with radiation.10,11 rP increases testosterone and free 
testosterone, estradiol, lh and FSh serum levels and 
decreases dht serum level in one-year period.10 In 
patients treated by rP, the baseline testosterone level is 
almost twice as higher in the low-grade tumors group 
than in the high-grade tumors group; there is also 
doubling of testosterone in 12-months period in the 
high-grade tumors group in comparison to the low-
grade tumors group.12 Patients with pre-operative low 
baseline testosterone level had mean gleason score 
higher and Ar expression was higher; significantly 
lower testosterone levels were recorded in patients 
with lymph node metastases.13,14 low baseline testos-
terone level at diagnosis of PC is associated with ag-
gressive type of PC and predicts poor PC-specific sur-
vival, the low testosterone group had 10,7-fold in-
creased risk of the PC-specific mortality.15 Further-
more, low (but not necessarily castration) testosterone 
levels at the time of first PSA failure confer a very poor 
prognosis, a significant increase in the risk of all-cause 
mortality and PC-specific mortality.16 Still, some data 
are conflicting and some results are opposite to those 
mentioned before. These data showed that there is no 
significant association between all sex hormone in 
men and lethal PC or total mortality. There was no 
consistent association between lethal PC and sex hor-
mone quartile in subset analyses stratified by gleason 
score, tnm stage and age.18-20 In patients with meta-
static PC, results showed that elevation of baseline an-
drostenedione levels was predictive of PSA response; 
higher baseline androstenedione level were associated 
with an improved overall survival.21 In patients treated 
by AA+prednisone results showed longer survival in 
comparison to prednisone alone in the above- or be-
low-median group for all androgens.22 In patients 
treated by non-hormonal first-line chemotherapy, me-
dian overall survival was significantly longer if baseline 
testosterone level was above than under the testoster-
one level median value.23 large systematic review and 
meta-analysis in 2018 showed that serum testosterone 
level was not prognostic in terms of overall survival 
and biochemical recurrence in early-stage PC studies. 
In advanced PC studies, higher testosterone levels be-
fore Adt were associated with a reduced risk of death; 
but during Adt, lower testosterone levels were associ-
ated with a reduced risk of death and PC progression. 
In mCrPC studies, higher testosterone levels predict-
ed a reduced risk of PC progression, but not of death. 
The relationship between serum testosterone and PC 
prognosis varies in different clinical settings and ac-
cording to Adt administration.24 The association be-
tween serum testosterone levels and PC biology is 
complex and changes dynamically, during the course of 
the disease. Still, some mechanisms of its interaction 
are unknown and deserve to be studied further.
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Sažetak
Je lI teStoSteron PrognoStIČKI VAŽAn u lIJeČenJu rAKA ProStAte.  
uroloŠKo StAJAlIŠte.
T. Sorić i I. Vidić
Karcinom prostate (KP) je androgen-ovisan tumor kojem je testosteron prirodni faktor rasta, njegovo djelovanje je po-
sredovano putem androgenih receptora (Ar) važnih za biologiju i progresiju KP. tijekom starenja započinje progresivni pad 
serumske razine testosterona uzrokovan nesposobnošću ostarjelih leydigovih stanica za stvaranje testosterona kao odgovor 
na stimulaciju luteinizirajućeg hormona. Kirurško liječenje KP može utjecati na os hipotalamus-hipofiza-gonade, ali s ma-
njim utjecajem u usporedbi s pacijentima liječenim radioterapijom. Kod pacijenata s nižim preoperativnim razinama testo-
sterona bilježe se povišene srednje vrijednosti gleason zbroja i pojačana ekspresija Ar; značajno niže razine testosterona 
zabilježene su kod pacijenata s metastazama u limfnim čvorovima. Ipak, neki podaci su kontradiktorni i u suprotnosti s 
prethodno navedenim. ovi podaci pokazuju da ne postoji značajna povezanost između spolnih hormona u muškaraca i letal-
nog KP te ukupnog mortaliteta. Kod pacijenata s metastatskim KP, elevacija početnih razina androstendiona se pokazala 
prediktivnom u odgovoru prostata-specifičnog antigena (PSA) i poboljšanju općeg preživljenja. Kod tih pacijenata, odnos 
između serumskih razina testosterona i prognoze KP varira u različitim kliničkim okolnostima i ovisno o aplikaciji androgen 
deprivacijske terapije.
Ključne riječi: rak prostate, androgen deprivacijska terapija, metastatski karcinom prostate, testosteron u serumu
